genetically modified mice, we investigated the mechanism(s) through which MPO activates endothelial calpain. We also studied the molecular targets and functional consequences of MPO/calpain signaling in the mouse aortic endothelium.
P
reclinical studies indicate that circulating cells of the myeloid compartment, namely neutrophils and monocytes, play an important role in the initiation and progression of vascular disease. 1 In humans, activation of neutrophils and monocytes is highly associated with cardiovascular events. 2, 3 Accordingly, epidemiological studies have associated leukocytes with cardiovascular disease, 4 which underlines their role in low-grade inflammatory disorders of the vasculature.
MPO (myeloperoxidase) is a major neutrophil effector protein, accounting for ≈5% of the cell's dry mass, and it is also present in monocytes, where it comprises one-third of the MPO content found in neutrophils. MPO and its byproducts have been shown to contribute to endothelial dysfunction, 5 hypertension, 6 and rupture of atherosclerotic plaques. 7 Plasma and serum levels of MPO independently predict endothelial dysfunction of large arteries in cardiovascular patients, 5, 8 and individuals who have higher MPO levels are 15-fold to 20-fold more likely to demonstrate abnormal coronary angiograms. 9 Conversely, a promoter polymorphism associated with a 2-fold reduction in MPO expression protects from vascular disease and cardiac death. 10 Surprisingly, very little information is available in the scientific literature to explain the molecular mechanism(s) through which MPO impairs endothelial function, which limits therapeutic intervention in humans.
Calpain is a Ca 2+ dependent, cysteine protease 11 whose activity is regulated, among other factors, by its endogenous inhibitor, calpastatin. 12 Two calpain isoforms, µ-calpain and m-calpain, are expressed in endothelial cells, 13 where they have been shown to affect nitric oxide (NO) generation 14 and endothelial adhesiveness to leukocytes. 15 Moreover, inhibition of calpain attenuates endothelial dysfunction in acute 16 and chronic 17 inflammatory states of the cardiovascular system. We hypothesized a role for calpain in the endothelial dysfunction induced by MPO. Using pharmacological tools and Figure 1 . MPO (myeloperoxidase) activates µ-calpain in endothelial cells. Upper graph, Serum starved mouse lung microvascular endothelial cells (MMVEC) were incubated with 10 nmol/L MPO and calpain activity was measured at 60, 120, 180, and 240 min using the calpain specific fluorogenic substrate Succ-LLVY-AMC. Lower graph, MMVEC were then incubated with either vehicle (8 µL PBS) or 10 nmol/L MPO for 180 min with or without ZLLal (100 µmol/L, 30 min pretreatment). The activity of the µ-calpain isoform was assessed by immunoblot analysis using a primary antibody that recognizes loss of expression of the N-terminus domain of µ-calpain large subunit. Loss of N-terminus domain indicates calpain activation. An antibody against µ-calpain large subunit C-terminus domain was used to quantify total µ-calpain expression. β-actin detection was used as a loading control. Representative immunoblot demonstrates cleavage of MMVEC µ-calpain N-terminus domain after incubation with 10 nmol/L MPO for 180 min. Bar graph summarizes densitometry quantification of µ-calpain N-terminus domain. Total µ-calpain expression level was not changed by MPO, as demonstrated C-terminus domain immunoblot. Data are mean±SEM of 4 (upper graph) and 6 to 8 (lower graph) independent experiments. NS indicates nonsignificant.
Results

MPO Activates the Endothelial µ-Calpain Isoform
Data shown in Figure 1 (upper) demonstrate that exposure of MMVEC to 10 nmol/L MPO causes a time-dependent increase in calpain activity, with near maximum activity reached after 180 minutes. The MPO concentration used in our study was based on the results of dose-response curves ( Figure S2 in the online-only Data Supplement), and it is in the range of MPO plasma levels found in humans with coronary artery disease. 20 To identify the calpain isoforms activated by MPO, we then measured expression levels of the N-terminus domain of the 80 kDa subunit of both m-calpain and µ-calpain. On activation, calpains undergo autoproteolysis with removal of the 9 to 15 amino acids of the N-terminus domain. Cleavage of the N-terminus domain was then detected by immunoblot analyses as loss of N-terminus domain recognition (see also Method section). MMVEC exposed to MPO experience loss of expression of the N-terminus domain of μ-calpain ( Figure 1 , lower graph; Figure S1A ), but not that of m-calpain ( Figure S3 ). To rule out nonspecific degradation of µ-calpain by MPO, we quantified total μ-calpain expression using a primary antibody against domain IV of the large subunit, which recognizes both unautolyzed and autolyzed µ-calpain. As shown in Figure 1 (lower graph) MPO did not cause significant changes in µ-calpain expression level. Similarly, µ-calpain mRNA levels were not significantly changed by MPO ( Figure S4 ). In parallel experiments, the activating effect of MPO on µ-calpain was blocked by pretreatment of MMVEC with 100 µmol/L ZLLal, a selective calpain inhibitor. 17 Data shown in Figure 1 (lower graph), demonstrate that ZLLal effectively prevented calpain activation in response to MPO. Taken together, these data demonstrate that MPO activates µ-calpain in endothelial cells, and that this process is amenable to pharmacological inhibition.
Mechanism(s) Through Which MPO Activates µ-Calpain
To investigate the mechanism(s) responsible for µ-calpain activation, we first measured the effect of MPO on calpastatin, which is the endogenous inhibitor of calpain.
11 Figure 2 and Figure S1B show reduced calpastatin abundance in MMVEC exposed to 10 nmol/L MPO. At first, this result suggested that degradation of calpastatin by MPO could be the mechanism responsible for activation of µ-calpain. Data in the literature though have reported loss of calpastatin in the presence of active calpains, because of the fact that calpastatin itself is a calpain substrate.
11 Accordingly, we studied whether the loss of calpastatin in MPO-treated MMVEC was secondary to calpain activation. Indeed, MPO failed to reduce calpastatin levels in MMVEC pretreated with the calpain inhibitor ZLLal (Figures 2 and S1B), thus confirming that, under our experimental conditions, loss of calpastatin is secondary to, and because of µ-calpain activation. Consistent with these results calpastatin mRNA expression levels were also not significantly changed ( Figure S4 ). These data indicate that MPO alters the calpain/calpastatin balance in endothelial cells by causing sustained activation of µ-calpain with subsequent degradation of calpastatin. We then tested whether MPO activates calpain via a nitrosylation-mediated mechanism. Studies have shown that NO inactivates calpains by nitrosylation, 21 and that denitrosylation increases calpain activity. 22 Therefore, we measured μ-calpain nitrosylation levels in MMVEC exposed to MPO The expression of the endogenous calpain inhibitor calpastatin was measured by immunoblot analysis and quantified by densitometry. β-actin detection was used as a loading control. Data are mean±SEM of 6 to 7 independent experiments. April 2018 using a previously described biotin switch assay. 23 As shown in Figure 3 , MPO reduces μ-calpain nitrosylation levels in MMVEC. These data suggested that perturbation in the eNOS (endothelial nitric oxide synthase)/NO biosynthetic machinery is a probable mechanism through which MPO activates the endothelial calpain system.
µ-Calpain Plays a Role in the Mechanism Through Which MPO Decreases AMPK/eNOS Phosphorylation
Phosphorylation of eNOS at Ser 1177 is required for maintaining physiological levels of NO in the vascular endothelium. 24 Thus, we tested the hypothesis that MPO impairs Ser 1177 eNOS phosphorylation thereby sustaining calpain denitrosylation. Data shown in the Figure 4 (upper graph) demonstrate that MPO significantly decreases Ser 1177 eNOS phosphorylation in MMVEC in the absence of significant changes in total eNOS expression. Studies have demonstrated that in endothelial cells the energy sensing kinase AMPK (AMP-activated protein kinase) activates eNOS through Ser 1177 phosphorylation. 25 Interestingly, studies have shown that calpain can affect AMPK expression and phosphorylation of its Thr 172 activation site. 26 Data shown in Figure 4 (lower graph) demonstrate a significant decrease in AMPK Thr 172 phosphorylation whereas total AMPK expression remained unchanged in MMVEC exposed to MPO. Treatment of MMVEC with the calpain inhibitor ZLLal restored AMPK and eNOS phosphorylation in the presence of MPO (Figure 4 ; Figure S1C and S1D), which suggests the existence of a feed-forward control mechanism through which in response to MPO active calpains maintain a denitrosylated status by sustaining downregulation of AMPK/eNOS signaling. Akt also activates eNOS via Ser 1177 phosphorylation. 24 Therefore, we also measured Akt activity with Ser 473 Akt phosphorylation in response to MPO, which was found to be reduced by MPO in a noncalpain-dependent manner ( Figures S5 and S1K ).
Mechanism Through Which MPO/Calpain Signaling Affects Thr 172 AMPK Phosphorylation
First, we studied the effect of MPO on the LKB1 (liver kinase B1), which is the main kinase to phosphorylate AMPK at Thr 172 . 27 MPO did not significantly change LKB1 expression levels in MMVEC under our experimental conditions ( Figure 5 , upper graph; Figure S1E ). Second, we investigated the role of the PP2A (protein phosphatase 2A), a signaling partner of active calpains 28 that has also been shown to inhibit AMPK activity via Thr 172 dephosphorylation. 29 Interestingly, MPO increased the expression level of the catalytic subunit of PP2A in MMVEC ( Figure 5 , middle graph; Figure S1F ). In agreement with the data on AMPK/eNOS phosphorylation summarized in Figure 4 , the effect of MPO on PP2A were abolished by treatment of MMVEC with ZLLal ( Figure 5 , middle graph; Figure S1F ). To obtain mechanistic evidence that the effect of MPO/calpain signaling on AMPK phosphorylation is indeed PP2A dependent, we pretreated MMVEC with the PP2A inhibitor okadaic acid. Results shown in Figure 5 (lower graph) and in Figure S1G demonstrate that direct inhibition of PP2A preserves phospho-AMPK levels in MMVEC in the presence of MPO. 29 These data uncover PP2A as an important downstream mediator of endothelial dysfunction in response to MPO/calpain signaling. 
Mechanistic Role of Calpain in MPO-Induced Increased Endothelial Adhesiveness to Leukocytes
To investigate the impact of MPO/calpain signaling on endothelial function we measured the expression level of the endothelial cell adhesion molecule VCAM-1 (vascular cell adhesion protein 1), an adhesion molecule upregulated by dysfunctional endothelia with impaired eNOS function. 30 VCAM-1 expression levels are elevated in MMVEC cells treated with MPO ( Figure 6 , upper graph; Figure S1H ). Consistent with the biochemical data reported above, VCAM-1 protein levels were attenuated by treatment with ZLLal.
Endothelia expressing VCAM-1 becomes adhesive to circulating leukocytes. 31 Accordingly, we next studied the effect of MPO/calpain signaling on the adhesion of leukocytes to the aortic endothelium. For these studies, aortas and leukocytes were isolated from male wild-type/control C57BL/6J and µ-calpain deficient mice (Capn1 −/− ). Lack of calpain expression was confirmed by Western blot analyses ( Figure S6 ). No significant differences in body weight, systemic blood pressure (Table S1) , and total expression levels of eNOS and AMPK ( Figure S6 ), were detected between wild-type mice and Capn1 −/− mice. Data in Figure 6 show that in wild-type mice MPO increases the adhesion of leukocytes to the aortic endothelium. Compared with control aortas, MPO-stimulated aortas showed a significantly higher number of adhered leukocytes, which was prevented by treatment of aortas with ZLLal ( Figure 6 , lower graph). Additional mechanistic studies with Capn1 −/− mice were undertaken to dissect the individual contribution of endothelial-expressed and leukocyte-expressed µ-calpain. MPO failed to increase the adhesion of leukocytes isolated from wild-type mice to the aortic endothelium of µ-calpain deficient mice. In contrast, increased leukocyte adhesion by MPO was observed in wild-type mouse aortas incubated with Capn1 −/− mouse leukocytes ( Figure 6, lower graph) . Thus, endothelialexpressed µ-calpain is a requirement for MPO to increases leukocyte-endothelium interactions. These data agree with data on VCAM-1 expression and they demonstrate that in the setting of increased MPO signaling, the vascular endothelium develops a calpain-dependent, proadhesive phenotype to leukocytes.
Discussion
The current study is, to our knowledge, the first to uncover the role of the cytosolic protease µ-calpain in the endothelial dysfunction associated with elevated levels of MPO. We show that a concentration of MPO in the range of those found in the plasma of humans with cardiovascular disease activates the µ-calpain isoform in endothelial cells, which induces an adhesive phenotype in the mouse aorta. Noteworthy, we also show that activation of µ-calpain by MPO is amenable to pharmacological inhibition, which makes the endothelial calpain system an attractive, novel therapeutic target in cardiovascular disease.
Clinical studies have found a direct correlation between serum MPO levels and endothelial dysfunction; a correlation found to be stronger than that of CRP (C-reactive protein). 5 Because MPO reacts with NO, enhancing its catabolism, 8 current views consider direct interaction of MPO with NO as the primary mechanism underlying MPOdependent alteration in endothelial function. This theory is based on seminal findings in animal models of sepsis demonstrating that MPO released by leukocytes localizes in and around endothelial cells of the aorta, where it drives catalytic consumption of NO. 32 This working model, though, does not address more recent studies demonstrating a direct inhibitory action of MPO and its derived metabolites on eNOS activity. 33, 34 Our study uncovers a novel endothelial signaling mechanism, involving the calpain system, through which MPO decreases eNOS Ser 1177 phosphorylation, thus causing endothelial dysfunction beyond catalytic consumption of NO ( Figure S7 ). Thus, it is possible that after initial degradation of NO, more stable signaling alterations of eNOS take place in vascular endothelia exposed to MPO. The activation of calpain seen in our study could then help explain recent data reporting decreased eNOS function after exposure of endothelial cells to MPO byproducts. 33 Our Lower graph, Circulating leukocytes and thoracic aortas were isolated from C57BLK and µ-calpain −/− donor mice. Leukocytes were fluorescently labeled as reported in the Method section. Isolated 2 mm length aortic segments were first exposed to 10 nmol/L MPO for 180 min. Aortic segments were then washed and coincubated endothelial surface up with leukocytes for an additional 60 min. In parallel experiments, inhibition of calpain activity by ZLLal also prevented adhesion of leukocytes to the wild-type aorta exposed to MPO. Data are mean±SEM of 6 aortic segments from 3 mice per group. A total of 54 aortic segments were studied. NS indicates nonsignificant.
results also provide a molecular explanation to the evidence of increased NO bioavailability after calpain inhibition in cultured endothelial cells, 35 and in animal models of vascular inflammation. 36 Several kinases regulate eNOS by phosphorylating its activation and inhibition sites. Noteworthy, phosphorylation at Ser 1177 , which is catalyzed by several distinct kinases including AMPK 25 and AKT (protein kinase B) 37 confers the most important positive modulation of eNOS activity, thereby increases NO production. 38 In our study, MPO impaired the phosphorylation of both kinases, thus suggesting that binding of MPO to the vascular endothelium affects the activity of multiple kinases. Unique though to AMPK signaling, we found evidence that inhibition of calpain could restore both AMPK and eNOS Ser 1177 phosphorylation in the face of MPO. We have also identified PP2A induction as a new molecular mechanism through which the MPO/calpain pathway downregulates AMPK. This result is consistent with evidence that AMPK alone can phosphorylate and activate eNOS at Ser 1177 , 25 and it also agrees with the prevailing theory that Ser 1177 eNOS phosphorylation by diverse kinases is stimuli dependent and therefore regulated through multisite phosphorylation in different pathologies. 39 Of note, AMPK is an energy sensor/metabolic switch, because it phosphorylates and hence regulates the activity of enzymes such as acetylCoA carboxylase and HMG-CoA reductase. 40, 41 Interestingly, MPO has been recently shown to cause endothelial dysfunction in metabolic disorders such as hyperglycemia, obesity, and preeclampsia. [42] [43] [44] [45] Thus, it is possible that modulation of the calpain system may, at least in part, restore AMPK/ eNOS signaling in the endothelial dysfunction of dysmetabolic states.
An unexpected, innovative result of our work is found in the mechanism through which MPO activates µ-calpain in the vascular endothelium. Our data demonstrate that reduced calpain nitrosylation occurs in endothelial cells exposed to MPO, which is in agreement with a recent study reporting a role for nitrosylation in the regulation of µ-calpain activity. 22 Others have also reported inhibition of calpain activity by NO. 46, 47 Thus, a feedback regulation is likely to exist between the eNOS/NO biosynthetic machinery and the calpain system in the inflamed vascular endothelium. In the setting of inflammation, large amounts of NO can be produced also by iNOS (inducible nitric oxide synthase), and data in the literature demonstrate that MPO can increase the catalytic activity of iNOS 48 in vitro. In contrast, others have demonstrated that, in the in vivo setting of inflammation, MPO downregulates iNOS expression. 49 Induction of iNOS, however, requires a longer period of time then the 3-hour protocol adopted in this study, 50 and therefore was not likely to play a significant role.
Curiously, both calpain and eNOS require elevation in cytosolic calcium levels for activation, which in theory should consistently hinder physiological eNOS function because active calpain can downregulate eNOS. 51 This apparent paradox is explained, at least in part, by 3 lines of evidence. First, in response to calcium signaling, binding of eNOS to HPS90 (heat shock protein 90) renders eNOS resistant to calpain digestion. 52 58 In addition to its vasodilatory properties, basal levels of endothelial NO maintain an antiadhesive phenotype in the vascular endothelium, thus preventing abnormal infiltration of leukocytes in the vascular wall. 30, 59 Relevant here, endothelial NO has been shown to prevent upregulation of VCAM-1 in response to inflammatory stimuli. 30 We found that MPO increases expression levels of VCAM-1 in microvascular endothelial cells, in addition to increasing adhesion of leukocytes to the mouse aorta via a calpain-dependent mechanism. In agreement with our results, others have demonstrated an association between MPO and increased leukocyte adhesion to the vascular endothelium, 60 including the endothelium of the microcirculation. 61 Data also demonstrate that µ-calpain increases expression of cell adhesion molecules in endothelial cells. 62 Conversely, inhibiting calpain reduces the adverse outcomes of ischemia reperfusion injury by reducing ICAM-1 (intercellular adhesion molecule 1) expression and preventing neutrophil infiltration. 63 In previous studies, we have also reported that inhibition of calpain activity prevents adhesion of leukocytes in the hyperglycemic microcirculation of diabetic rats. 17 Thus, inhibition of calpain attenuates adhesion of leukocytes to the vascular endothelium of both large conduit vessels and microcirculation which is in agreement with our in vitro and in vivo findings, respectively.
Interaction of circulating leukocytes with the vascular endothelium is governed by adhesion molecules expressed on the cell surface of both cell types. µ-calpain is also constitutively expressed both in circulating leukocytes 64 and endothelial cells. 13 Thus, we asked whether leukocyteexpressed µ-calpain played a role in these studies. We found evidence that aortas of mice deficient in µ-calpain are protected against leukocyte adhesion induced by MPO, which indicates an obligatory role for endothelial-expressed calpains in the initiation of vascular inflammation in response to MPO. This conclusion is supported by data from our laboratory and others demonstrating that leukocyte-endothelium interactions can be largely abrogated by direct blockade of adhesion molecules expressed on the vascular endothelium only. 65, 66 Nonetheless, it should be noted that endothelial-expressed calpains have been shown to influence the adhesive and migratory behavior of circulating leukocytes. 67 Conversely, adhesion of leukocytes initiates calcium signaling events that lead to activation of the endothelial calpain system. 15 Obviously, further studies are needed to fully dissect how different inflammatory stimuli and duration of inflammation affect the calpain system of leukocytes and endothelial cells.
Perspectives
Preclinical and clinical research has indisputably confirmed the role of MPO in cardiovascular disease. The endothelium and eNOS are now well-established cellular and molecular targets of the cardiovascular damaging actions of MPO. Thus, MPO is an attractive target for therapeutic intervention in cardiovascular disease. Several selective MPO inhibitors have been developed in recent years. The necessity of preserving MPO immunodefensive functions, though, poses a major challenge to inhibition of MPO for therapeutic treatment. Perhaps, the uncovering of MPO downstream inflammatory pathways in relevant cells of the cardiovascular system will provide more selective pharmacological targets to hinder pathological activation of MPO, whereas preserving its beneficial host defense function. This study first identifies in endothelial-expressed calpain a new molecular target of MPO in the vascular wall thus providing new therapeutic targets. We also first report that increased calpain activity downregulates AMPK/eNOS signaling in endothelial cells via activation of the PP2A, which extends the current working model that direct catalytic consumption of NO is the main mechanism through which MPO causes endothelial dysfunction. Furthermore, the implication of the energy sensing kinase, AMPK, in the endothelial dysfunction of MPO raises new intriguing questions on the role that MPO plays in the cardiovascular disease associated with the metabolic syndrome.
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